Drug Profile
Research programme: rare diseases and cancer therapeutics - OrphAI Therapeutics
Alternative Names: Rare disease therapeutics - OrphAI TherapeuticsLatest Information Update: 04 Oct 2023
Price :
$50
*
At a glance
- Originator LAM Therapeutics
- Developer OrphAI Therapeutics
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Unspecified
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for preclinical development in Unspecified in USA
- 28 Mar 2020 No recent reports of development identified for research development in Cancer in USA
- 12 Dec 2018 Preclinical trials in Unspecified (rare disease indication) in USA (unspecified route) (AI Therapeutics pipeline, December 2018)